Condition: Advanced Gastric Cancer · Metastatic Gastric Cancer · Gastroesophageal Junction Adenocarcinoma · Sponsor: Jiangsu HengRui Medicine Co., Ltd.
This is a multicenter, phase 2, open label study to evaluate safety, tolerability and efficacy of SHR2554 combined with other anti-tumor treatments in patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
This description comes directly from the study's public registry record.
Botao Zhu · +86-021-23511999 · botao.zhu.bz19@hengrui.com
Always discuss trial participation with your own doctor first.
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang, China | Recruiting |
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou, Henan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07102901